retatrutide vs orforglipron trial results news today Lilly's triple agonist achieves 16.8% weight loss in phase 3 Lilly oral GLP-1 phase – YouTube

In this episode, Mark Hyman, M Would you like access to extensive show notes and references for this podcast (and more)

Persistent pain, increasing swelling, warmth, or signs of infection warrant contact with your healthcare provider

4-6% placebo Diarrhea: 12-17% Vomiting: 5-10% Constipation: 6-11% Decreased appetite: 5-11% GI events are predominantly mild-moderate and occur mainly during dose escalation (first 4-8 weeks), with significant attenuation over time Serious adverse events of interest : Pancreatitis : Adjudicated pancreatitis events occurred at rates of approximately 0.1-0.2% across the SURPASS program, comparable to rates seen with GLP-1 agonists

Capsule Material & Color Options We offer a selection of capsule shells, including Vegan and Gelatin-based materials, in a variety of standard colors